Hypophosphatemic Rickets in Norway

• Conditions: Hyperphosphatemia; Hypophosphatemia, Familial; Rickets
• Interventions: Dietary Supplement: Alfacalcidol; phosphate.; Drug: Sevelamer

• Registration Number: NCT01057186
• Lead Sponsor: Haukeland University Hospital

Brief Summary

The purpose of the study is to do a follow-up survey of all individuals with hereditary hypophosphatemia in Norway, focusing on manifestations in childhood and adolescence. The investigators also want to study phenotype-genotype associations, and look for new genes, in all forms of hereditary hypo and hyperphosphatemia.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-12
• Study First Submitted: 2010-01-26
• Study First Submitted QC: 2010-01-26
• Study First Posted: 2010-01-27
• Status Verified: 2016-08
• Last Update Submitted: 2016-08-30
• Last Update Posted: 2016-08-31
• Primary Completion: 2018-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• All patients in the Norwegian population with hereditary hypophosphatemia, with or without rickets
• Patients in the Norwegian population with hereditary hyperphosphatemia

Exclusion Criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
hereditary hypophosphatemia	Alfacalcidol; phosphate.	Norwegian patients with hereditary hypophosphatemia.
Hereditary hyperphosphatemia	Sevelamer	Norwegian patients with hereditary hyperphosphatemia (hyperphosphatemic familial tumoral calcinosis and hyperphosphatemia hyperostosis syndrome).

Primary Outcome Measures

Name	Time	Method
Growth	Up to 18 years	Change i height z-score from time of diagnosis to last registered consultation.

Trial Locations

Locations (1)

Haukeland University Hospital, Childrens departement; 🇳🇴 Bergen, Norway